Skip to main content
PMC home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1995 Jul;147(1):114–123.

Prognostic role of urokinase-type plasminogen activator in human gliomas.

D W Hsu 1, J T Efird 1, E T Hedley-Whyte 1
PMCID: PMC1869896  PMID: 7604873

Abstract

Urokinase-type plasminogen activator (u-PA) is a 54-kd enzyme shown to participate in tissue degradation under certain normal and pathological conditions, including cancer invasion and metastasis. Increased u-PA expression has been found in cancers of the breast, lung, colon, and prostate, and correlated with worse outcome in patients with lung and breast cancer. We examined the correlation between u-PA expression in gliomas and patient survival. Seventy-seven gliomas from 41 men and 36 women (ages 2 to 73) were immunostained for u-PA using monoclonal antibody 394 directed against human urokinase. The tumors included 32 grade 4, 16 grade 3, and 20 grade 2 astrocytomas (Daumas-Duport scale), and 9 pilocytic astrocytomas. Strong cytoplasmic staining was found in tumor cells of all grade 4, most of the grade 3, and a few of the lower grade tumors. Adjacent normal brain tissue showed faint staining associated with subpial cell processes and white matter fibers. The fiber staining was stronger in brain tissue infiltrated by tumor cells. Cytoplasmic u-PA staining in tumor cells was scored from 0 (no staining) to 6 (strong and widespread staining). The mean u-PA scores were 5.08 +/- 0.19 (mean +/- SEM) for grade 4, 3.97 +/- 0.46 for grade 3, 1.65 +/- 0.39 for grade 2, and 1.22 +/- 0.60 for pilocytic astrocytomas. The statistical analysis was based on cytoplasmic staining only. Analysis of variance revealed significant differences between the mean u-PA scores of different grades (P < 0.02 between grades 4 and 3, and P = 0.0001 between grades 4 or 3 and 2, and between grades 4 or 3 and pilocytic), except between grade 2 and pilocytic astrocytomas. Univariate analysis indicated that u-PA score > or = 4 (P = 0.0001), tumor grade 4 (P = 0.01), and age > 50 (P < 0.001) were all significant predictors for shorter disease survival. A three-way interaction model by multivariate analysis indicated that u-PA score > or = 4, tumor grade 4, and age > 50, taken together, were significant factors for shorter patient survival (P < 0.02). We conclude that u-PA may be used as a prognostic tool in conjunction with tumor grade and patients' age in predicting survival for patients with gliomas.

Full text

PDF
114

Images in this article

117Figure 1
on p.117

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aoki N., Von Kaulla K. N. Dissimilarity of human vascular plasminogen activator and human urokinase. J Lab Clin Med. 1971 Sep;78(3):354–362. [PubMed] [Google Scholar]
  2. Camiolo S. M., Markus G., Englander L. S., Siuta M. R., Hobika G. H., Kohga S. Plasminogen activator content and secretion in explants of neoplastic and benign human prostate tissues. Cancer Res. 1984 Jan;44(1):311–318. [PubMed] [Google Scholar]
  3. Danø K., Andreasen P. A., Grøndahl-Hansen J., Kristensen P., Nielsen L. S., Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985;44:139–266. doi: 10.1016/s0065-230x(08)60028-7. [DOI] [PubMed] [Google Scholar]
  4. Danø K., Dabelsteen E., Nielsen L. S., Kaltoft K., Wilson E. L., Zeuthen J. Plasminogen activating enzyme in cultured glioblastoma cells. An immunofluorescence study with monoclonal antibody. J Histochem Cytochem. 1982 Nov;30(11):1165–1170. doi: 10.1177/30.11.6183313. [DOI] [PubMed] [Google Scholar]
  5. Daumas-Duport C., Scheithauer B., O'Fallon J., Kelly P. Grading of astrocytomas. A simple and reproducible method. Cancer. 1988 Nov 15;62(10):2152–2165. doi: 10.1002/1097-0142(19881115)62:10<2152::aid-cncr2820621015>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  6. Duffy M. J., O'Grady P., Devaney D., O'Siorain L., Fennelly J. J., Lijnen H. J. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer. 1988 Aug 1;62(3):531–533. doi: 10.1002/1097-0142(19880801)62:3<531::aid-cncr2820620315>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  7. Duffy M. J., Reilly D., O'Sullivan C., O'Higgins N., Fennelly J. J., Andreasen P. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res. 1990 Nov 1;50(21):6827–6829. [PubMed] [Google Scholar]
  8. Ellis V., Behrendt N., Danø K. Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem. 1991 Jul 5;266(19):12752–12758. [PubMed] [Google Scholar]
  9. Franks A. J., Ellis E. Immunohistochemical localisation of tissue plasminogen activator in human brain tumours. Br J Cancer. 1989 Mar;59(3):462–466. doi: 10.1038/bjc.1989.95. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gaylis F. D., Keer H. N., Wilson M. J., Kwaan H. C., Sinha A. A., Kozlowski J. M. Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype. J Urol. 1989 Jul;142(1):193–198. doi: 10.1016/s0022-5347(17)38709-8. [DOI] [PubMed] [Google Scholar]
  11. Guthrie D., Ross W. M., Latner A. L., Turner G. A., Way S. Effective treatment of a patient with an advanced carcinoma of the cervix with a combination of bromocriptine and aprotinin. Br J Clin Pract. 1981 Sep;35(9):330–332. [PubMed] [Google Scholar]
  12. Jankun J., Merrick H. W., Goldblatt P. J. Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. J Cell Biochem. 1993 Oct;53(2):135–144. doi: 10.1002/jcb.240530206. [DOI] [PubMed] [Google Scholar]
  13. Jänicke F., Schmitt M., Ulm K., Gössner W., Graeff H. Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet. 1989 Oct 28;2(8670):1049–1049. doi: 10.1016/s0140-6736(89)91070-2. [DOI] [PubMed] [Google Scholar]
  14. Kaltoft K., Nielsen L. S., Zeuthen J., Danø K. Monoclonal antibody that specifically inhibits a human Mr 52,000 plasminogen-activating enzyme. Proc Natl Acad Sci U S A. 1982 Jun;79(12):3720–3723. doi: 10.1073/pnas.79.12.3720. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kim T. S., Halliday A. L., Hedley-Whyte E. T., Convery K. Correlates of survival and the Daumas-Duport grading system for astrocytomas. J Neurosurg. 1991 Jan;74(1):27–37. doi: 10.3171/jns.1991.74.1.0027. [DOI] [PubMed] [Google Scholar]
  16. Kirchheimer J., Köller A., Binder B. R. Isolation and characterization of plasminogen activators from hyperplastic and malignant prostate tissue. Biochim Biophys Acta. 1984 Feb 14;797(2):256–265. doi: 10.1016/0304-4165(84)90129-6. [DOI] [PubMed] [Google Scholar]
  17. Kobayashi H., Ohi H., Sugimura M., Shinohara H., Fujii T., Terao T. Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B. Cancer Res. 1992 Jul 1;52(13):3610–3614. [PubMed] [Google Scholar]
  18. Kohga S., Harvey S. R., Weaver R. M., Markus G. Localization of plasminogen activators in human colon cancer by immunoperoxidase staining. Cancer Res. 1985 Apr;45(4):1787–1796. [PubMed] [Google Scholar]
  19. Kono S., Rao J. S., Bruner J. M., Sawaya R. Immunohistochemical localization of plasminogen activator inhibitor type 1 in human brain tumors. J Neuropathol Exp Neurol. 1994 May;53(3):256–262. doi: 10.1097/00005072-199405000-00006. [DOI] [PubMed] [Google Scholar]
  20. Kristensen P., Larsson L. I., Nielsen L. S., Grøndahl-Hansen J., Andreasen P. A., Danø K. Human endothelial cells contain one type of plasminogen activator. FEBS Lett. 1984 Mar 12;168(1):33–37. doi: 10.1016/0014-5793(84)80201-x. [DOI] [PubMed] [Google Scholar]
  21. Krystosek A., Seeds N. W. Plasminogen activator secretion by granule neurons in cultures of developing cerebellum. Proc Natl Acad Sci U S A. 1981 Dec;78(12):7810–7814. doi: 10.1073/pnas.78.12.7810. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Laiho M., Keski-Oja J. Growth factors in the regulation of pericellular proteolysis: a review. Cancer Res. 1989 May 15;49(10):2533–2553. [PubMed] [Google Scholar]
  23. Laws E. R., Jr, Thapar K. Brain tumors. CA Cancer J Clin. 1993 Sep-Oct;43(5):263–271. doi: 10.3322/canjclin.43.5.263. [DOI] [PubMed] [Google Scholar]
  24. Leon S. P., Zhu J., Black P. M. Genetic aberrations in human brain tumors. Neurosurgery. 1994 Apr;34(4):708–722. doi: 10.1227/00006123-199404000-00021. [DOI] [PubMed] [Google Scholar]
  25. Mahaley M. S., Jr, Mettlin C., Natarajan N., Laws E. R., Jr, Peace B. B. National survey of patterns of care for brain-tumor patients. J Neurosurg. 1989 Dec;71(6):826–836. doi: 10.3171/jns.1989.71.6.0826. [DOI] [PubMed] [Google Scholar]
  26. Markus G., Takita H., Camiolo S. M., Corasanti J. G., Evers J. L., Hobika G. H. Content and characterization of plasminogen activators in human lung tumors and normal lung tissue. Cancer Res. 1980 Mar;40(3):841–848. [PubMed] [Google Scholar]
  27. Miller S. J., Jensen P. J., Dzubow L. M., Lazarus G. S. Urokinase plasminogen activator is immunocytochemically detectable in squamous cell but not basal cell carcinomas. J Invest Dermatol. 1992 Mar;98(3):351–358. doi: 10.1111/1523-1747.ep12499803. [DOI] [PubMed] [Google Scholar]
  28. Moonen G., Grau-Wagemans M. P., Selak I., Lefebvre P. P., Rogister B., Vassalli J. D., Belin D. Plasminogen activator is a mitogen for astrocytes in developing cerebellum. Brain Res. 1985 May;352(1):41–48. doi: 10.1016/0165-3806(85)90085-9. [DOI] [PubMed] [Google Scholar]
  29. Nielsen L. S., Hansen J. G., Andreasen P. A., Skriver L., Danø K., Zeuthen J. Monoclonal antibody to human 66,000 molecular weight plasminogen activator from melanoma cells. Specific enzyme inhibition and one-step affinity purification. EMBO J. 1983;2(1):115–119. doi: 10.1002/j.1460-2075.1983.tb01391.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Oka T., Ishida T., Nishino T., Sugimachi K. Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma. Cancer Res. 1991 Jul 1;51(13):3522–3525. [PubMed] [Google Scholar]
  31. Ossowski L., Reich E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell. 1983 Dec;35(3 Pt 2):611–619. doi: 10.1016/0092-8674(83)90093-4. [DOI] [PubMed] [Google Scholar]
  32. Ossowski L., Russo-Payne H., Wilson E. L. Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. Cancer Res. 1991 Jan 1;51(1):274–281. [PubMed] [Google Scholar]
  33. Rajput B., Degen S. F., Reich E., Waller E. K., Axelrod J., Eddy R. L., Shows T. B. Chromosomal locations of human tissue plasminogen activator and urokinase genes. Science. 1985 Nov 8;230(4726):672–674. doi: 10.1126/science.3840278. [DOI] [PubMed] [Google Scholar]
  34. Sawaya R., Highsmith R. Plasminogen activator activity and molecular weight patterns in human brain tumors. J Neurosurg. 1988 Jan;68(1):73–79. doi: 10.3171/jns.1988.68.1.0073. [DOI] [PubMed] [Google Scholar]
  35. Sawaya R., Mandybur T., Ormsby I., Tew J. M., Jr Antifibrinolytic therapy of experimentally grown malignant brain tumors. J Neurosurg. 1986 Feb;64(2):263–268. doi: 10.3171/jns.1986.64.2.0263. [DOI] [PubMed] [Google Scholar]
  36. Sawaya R., Rämö O. J., Shi M. L., Mandybur G. Biological significance of tissue plasminogen activator content in brain tumors. J Neurosurg. 1991 Mar;74(3):480–486. doi: 10.3171/jns.1991.74.3.0480. [DOI] [PubMed] [Google Scholar]
  37. Sier C. F., Fellbaum C., Verspaget H. W., Schmitt M., Griffioen G., Graeff H., Hôfler H., Lamers C. B. Immunolocalization of urokinase-type plasminogen activator in adenomas and carcinomas of the colorectum. Histopathology. 1991 Sep;19(3):231–237. doi: 10.1111/j.1365-2559.1991.tb00027.x. [DOI] [PubMed] [Google Scholar]
  38. Soreq H., Miskin R. Plasminogen activator in the developing rat cerebellum: biosynthesis and localization in granular neurons. Brain Res. 1983 Dec;313(2):149–158. doi: 10.1016/0165-3806(83)90212-2. [DOI] [PubMed] [Google Scholar]
  39. Soreq H., Miskin R. Plasminogen activator in the rodent brain. Brain Res. 1981 Jul 20;216(2):361–374. doi: 10.1016/0006-8993(81)90138-4. [DOI] [PubMed] [Google Scholar]
  40. Sprengers E. D., Kluft C. Plasminogen activator inhibitors. Blood. 1987 Feb;69(2):381–387. [PubMed] [Google Scholar]
  41. Takai S., Yamamura M., Tanaka K., Kawanishi H., Tsuji M., Nakane Y., Hioki K., Yamamoto M. Plasminogen activators in human gastric cancers: correlation with DNA ploidy and immunohistochemical staining. Int J Cancer. 1991 Apr 22;48(1):20–27. doi: 10.1002/ijc.2910480105. [DOI] [PubMed] [Google Scholar]
  42. Tissot J. D., Hauert J., Bachmann F. Characterization of plasminogen activators from normal human breast and colon and from breast and colon carcinomas. Int J Cancer. 1984 Sep 15;34(3):295–302. doi: 10.1002/ijc.2910340302. [DOI] [PubMed] [Google Scholar]
  43. Tucker W. S., Kirsch W. M., Martinez-Hernandez A., Fink L. M. In vitro plasminogen activator activity in human brain tumors. Cancer Res. 1978 Feb;38(2):297–302. [PubMed] [Google Scholar]
  44. Vetterlein D., Young P. L., Bell T. E., Roblin R. Immunological characterization of multiple weight forms of human cell plasminogen activators. J Biol Chem. 1979 Feb 10;254(3):575–578. [PubMed] [Google Scholar]
  45. Wachsman J. T., Biedler J. L. Fibrinolytic activity associated with human neuroblastoma cells. Exp Cell Res. 1974 Jun;86(2):264–268. doi: 10.1016/0014-4827(74)90712-5. [DOI] [PubMed] [Google Scholar]
  46. Wilson E. L., Becker M. L., Hoal E. G., Dowdle E. B. Molecular species of plasminogen activators secreted by normal and neoplastic human cells. Cancer Res. 1980 Mar;40(3):933–938. [PubMed] [Google Scholar]
  47. Yamamoto M., Sawaya R., Mohanam S., Bindal A. K., Bruner J. M., Oka K., Rao V. H., Tomonaga M., Nicolson G. L., Rao J. S. Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo. Cancer Res. 1994 Jul 15;54(14):3656–3661. [PubMed] [Google Scholar]
  48. Yamamoto M., Sawaya R., Mohanam S., Loskutoff D. J., Bruner J. M., Rao V. H., Oka K., Tomonaga M., Nicolson G. L., Rao J. S. Expression and cellular localization of messenger RNA for plasminogen activator inhibitor type 1 in human astrocytomas in vivo. Cancer Res. 1994 Jul 1;54(13):3329–3332. [PubMed] [Google Scholar]
  49. Zänker K. S., Stavrou D., Blümel G. Fibrin degradation products, produced by glioma cell-associated fibrinolysis and the partial inhibition of cell growth and migration in tissue culture. Cell Mol Biol Incl Cyto Enzymol. 1979;25(6):387–394. [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES